Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Moderna's Valera Takes mRNA Approach To Combat Zika

Executive Summary

With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.

Advertisement

Related Content

Zika Vaccines Might Be Approved By 2020
Takeda In Hot Pursuit Of Zika Vaccine With $312m US Contract
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
Sanofi Teams With US Military On Zika, But Not For The Profits
Serious About Zika, Obama Seeks $1.8bn To Combat Virus

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097261

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel